Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bradley Theodore Hyman, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Bradley Hyman and Steven Greenberg.
Connection Strength

1.136
  1. Alzheimer disease's double-edged vaccine. Nat Med. 2003 Apr; 9(4):389-90.
    View in: PubMed
    Score: 0.276
  2. Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? Ann Neurol. 1997 Jun; 41(6):701-2.
    View in: PubMed
    Score: 0.185
  3. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995 Aug; 38(2):254-9.
    View in: PubMed
    Score: 0.162
  4. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett. 1999 Sep 17; 272(3):155-8.
    View in: PubMed
    Score: 0.054
  5. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet. 1998 Nov; 7(12):1953-6.
    View in: PubMed
    Score: 0.051
  6. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology. 1998 Apr; 50(4):961-5.
    View in: PubMed
    Score: 0.049
  7. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol. 1998 Apr; 57(4):353-9.
    View in: PubMed
    Score: 0.049
  8. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci. 1996 Dec 16; 802:1-5.
    View in: PubMed
    Score: 0.045
  9. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke. 1996 Aug; 27(8):1333-7.
    View in: PubMed
    Score: 0.044
  10. Lack of association of trinucleotide repeat polymorphisms in very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann Neurol. 1996 Jun; 39(6):800-3.
    View in: PubMed
    Score: 0.043
  11. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011 Jul; 7(4):367-85.
    View in: PubMed
    Score: 0.031
  12. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology. 2009 Jan 20; 72(3):268-72.
    View in: PubMed
    Score: 0.026
  13. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain. 2007 Sep; 130(Pt 9):2310-9.
    View in: PubMed
    Score: 0.023
  14. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007 Mar; 64(3):431-4.
    View in: PubMed
    Score: 0.023
  15. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. J Neurosci. 2006 Jan 11; 26(2):365-71.
    View in: PubMed
    Score: 0.021
  16. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005 Nov 08; 65(9):1402-8.
    View in: PubMed
    Score: 0.021
  17. Progression of cerebral amyloid angiopathy in transgenic mouse models of Alzheimer disease. J Neuropathol Exp Neurol. 2005 Jul; 64(7):588-94.
    View in: PubMed
    Score: 0.020
  18. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol. 2001 Apr; 60(4):342-9.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.